Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2001 1
2002 4
2003 2
2004 6
2005 5
2006 7
2007 4
2008 6
2009 9
2010 5
2011 6
2012 6
2013 4
2014 8
2015 3
2017 4
2018 3
2019 2
2020 1
2021 4
2022 3
2023 2
2024 2
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

85 results

Results by year

Filters applied: . Clear all
Page 1
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.
Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, Arnulf B, Macro M, Belhadj K, Garderet L, Roussel M, Payen C, Mathiot C, Fermand JP, Meuleman N, Rollet S, Maglio ME, Zeytoonjian AA, Weller EA, Munshi N, Anderson KC, Richardson PG, Facon T, Avet-Loiseau H, Harousseau JL, Moreau P; IFM 2009 Study. Attal M, et al. Among authors: lauwers cances v. N Engl J Med. 2017 Apr 6;376(14):1311-1320. doi: 10.1056/NEJMoa1611750. N Engl J Med. 2017. PMID: 28379796 Free PMC article. Clinical Trial.
Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.
Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, Stoppa AM, Hulin C, Benboubker L, Garderet L, Decaux O, Leyvraz S, Vekemans MC, Voillat L, Michallet M, Pegourie B, Dumontet C, Roussel M, Leleu X, Mathiot C, Payen C, Avet-Loiseau H, Harousseau JL; IFM Investigators. Attal M, et al. Among authors: lauwers cances v. N Engl J Med. 2012 May 10;366(19):1782-91. doi: 10.1056/NEJMoa1114138. N Engl J Med. 2012. PMID: 22571202 Free article. Clinical Trial.
Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.
Perrot A, Lauwers-Cances V, Corre J, Robillard N, Hulin C, Chretien ML, Dejoie T, Maheo S, Stoppa AM, Pegourie B, Karlin L, Garderet L, Arnulf B, Doyen C, Meuleman N, Royer B, Eveillard JR, Benboubker L, Dib M, Decaux O, Jaccard A, Belhadj K, Brechignac S, Kolb B, Fohrer C, Mohty M, Macro M, Richardson PG, Carlton V, Moorhead M, Willis T, Faham M, Anderson KC, Harousseau JL, Leleu X, Facon T, Moreau P, Attal M, Avet-Loiseau H, Munshi N. Perrot A, et al. Among authors: lauwers cances v. Blood. 2018 Dec 6;132(23):2456-2464. doi: 10.1182/blood-2018-06-858613. Epub 2018 Sep 24. Blood. 2018. PMID: 30249784 Free PMC article. Clinical Trial.
Twice-weekly induction with ixazomib-lenalidomide-dexamethasone (IRd) combination followed by extended IRd consolidation and lenalidomide maintenance in transplant-eligible patients with newly diagnosed multiple myeloma: Results of the phase 2 study IFM2014-03.
Perrot A, Roussel M, Lauwers-Cances V, Hulin C, Leleu X, Touzeau C, Facon T, Mariette C, Schiano JM, Gay J, Montes L, Ranta D, Huguet A, Wuillème S, Dejoie T, Devlamynck L, Corre J, Avet-Loiseau H, Moreau P, Attal M. Perrot A, et al. Among authors: lauwers cances v. Br J Haematol. 2024 Sep;205(3):891-899. doi: 10.1111/bjh.19570. Epub 2024 May 29. Br J Haematol. 2024. PMID: 38811169 Clinical Trial.
Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study.
Roussel M, Lauwers-Cances V, Macro M, Leleu X, Royer B, Hulin C, Karlin L, Perrot A, Touzeau C, Chrétien ML, Rigaudeau S, Dib M, Nicolas-Virelizier E, Escoffre-Barbe M, Belhadj K, Mariette C, Stoppa AM, Araujo C, Doyen C, Fontan J, Kolb B, Garderet L, Brechignac S, Malfuson JV, Jaccard A, Lenain P, Borel C, Hebraud B, Benbrahim O, Dorvaux V, Manier S, Augeul-Meunier K, Vekemans MC, Randriamalala E, Chaoui D, Caers J, Chaleteix C, Benboubker L, Vincent L, Glaisner S, Zunic P, Slama B, Eveillard JR, Humbrecht-Kraut C, Morel V, Mineur P, Eisenmann JC, Demarquette H, Richez V, Vignon M, Caillot D, Facon T, Moreau P, Colin AL, Olivier P, Wuilleme S, Avet-Loiseau H, Corre J, Attal M. Roussel M, et al. Among authors: lauwers cances v. Blood. 2022 May 5;139(18):2747-2757. doi: 10.1182/blood.2021014635. Blood. 2022. PMID: 35511184 Free article. Clinical Trial.
Electrostimulation mapping of spatial neglect.
Roux FE, Dufor O, Lauwers-Cances V, Boukhatem L, Brauge D, Draper L, Lotterie JA, Démonet JF. Roux FE, et al. Among authors: lauwers cances v. Neurosurgery. 2011 Dec;69(6):1218-31. doi: 10.1227/NEU.0b013e31822aefd2. Neurosurgery. 2011. PMID: 22067336
Category-specific cortical mapping: color-naming areas.
Roux FE, Lubrano V, Lauwers-Cances V, Mascott CR, Démonet JF. Roux FE, et al. Among authors: lauwers cances v. J Neurosurg. 2006 Jan;104(1):27-37. doi: 10.3171/jns.2006.104.1.27. J Neurosurg. 2006. PMID: 16509144
85 results